AUSTRIAN researchers have discovered that a small number of patients taking targeted drugs known as Janus kinase (JAK) inhibitors to treat myelofibrosis may develop aggressive lymphomas, according to a study published online in Blood, the Journal of the American Society of Hematology (ASH) - CLICK HERE.
There may be a way to screen for this risk, the authors speculate.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Jun 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Jun 18
